Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 1/20 | 0.62 |
| ▸ | JUN | P05412 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975428 | 1.00 | FOS (0.62) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL3452240 | 1.00 | FOS (0.62) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL80786 | 0.89 | FOS (0.72) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL30584119 | 0.89 | FOS (0.72) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL80787 | 0.89 | FOS (0.72) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL15932965 | 0.88 | MAOB (0.58) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8098406 | 0.87 | FOS (0.70) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL16410054 | 0.86 | MAOB (0.57) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL12698272 | 0.86 | MAOB (0.57) | FOSJUNBCHEMAOBSMN1; SMN2 | |
| SCHEMBL15929625 | 0.84 | MAOB (0.55) | FOSJUNBCHEMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1042320-B1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | ASTRAZENECA UK LTD (GB) | 2002-02-13 | — | — | EP | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| US-6218376-B1 | FOR TREATING INFLAMMATORY DISEASES | ASTRAZENECA UK LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |
| EP-1042320-A1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-10-11 | — | — | EP | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999026944-A1 | NEW COMPOUNDS WHICH ARE P2-PURINOCEPTOR 7-TRANSMEMBRANE (TM) G-PROTEIN COUPLED RECEPTOR ANTAGONISTS | ASTRAZENEKA UK LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | FOS 2856/4885JUN 2947/4885BCHE 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.